In Silico Neo-antigen Detection in High-grade Pediatric Brain Tumors Utilizing RNA-seq and WGS

Email Principal Investigator
Avoiding Immune Destruction
Asset 5.png

Peter Madsen

Children’s Hospital of Philadelphia
Philadelphia, PA, USA


About this


Immunotherapy, therapy that uses a patient’s own immune system to attack a tumor, is a promising form of therapy for high grade tumors such as high grade glioma, diffuse intrinsic pontine glioma (DIPG), atypical teratoid rhabdoid tumors (ATRT), and medulloblastoma. In these cases, there does not seem to be genetic targets for therapy, but rather the tumor growth is driven by epigenetic factors, or non-gene influences. The first step in identifying possible immunotherapy targets is identifying tumor neoantigens, or substances created by the tumor cells that affect cell processes. Researchers will use the Pediatric Brain Tumor Atlas to produce initial data for this study that could lead to the development of new patient-specific immunotherapies.

Ask The


Ask the scientists

What are the goals of this project?

Researchers will identify epigenetic factors, or non-gene influences on genes, that drive tumor growth, specifically in pediatric brain tumors without currently available drug targets.

What is the impact of this project?

This study will identify potential targets for immunotherapy treatments and deepen that understanding in a pursuit of real time patient-specific immunotherapies.

Why is the CBTN request important to this project?

Access to the Pediatric Brain Tumor Atlas provides researchers with the comprehensive data necessary to complete this initial study.

Specimen Data

The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.

Explore the data in these informatics portals